Calidi Biotherapeutics, a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two South Korean firms to advance manufacturing in preparation for Calidi's pre-IND and IND filings.
Eli Lilly is set to invest more than $470m to build a new pharmaceutical manufacturing facility in North Carolina, US.
The products are now a part of Armas' consistently growing product line, bringing their portfolio count to eleven
Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
US-based Amgen has closed the acquisition of a 20.5% stake in Chinese biopharmaceutical firm BeiGene for approximately $2.8bn to support the expansion of its oncology footprint in China.
GlaxoSmithKline (GSK) has completed the sale of its travel vaccines Rabipur for rabies, and Encepur for tick-borne encephalitis, to Bavarian Nordic.
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of $340m.
AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.